For the Inventor, By the Inventor

Enter assignee name

Abingdon, United Kingdom

Adaptimmune Limited

USPTO Granted Patents = 26

CIPO Patents = 4

EPO Patents = 29

Trademarks = 9

Forward Citations = 29

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Bent Karsten Jakobsen (11 out of 32 patents)

Peter Eamon Molloy (10 out of 17 patents)

Nicholas Tribble (7 out of 7 patents)

4. William Lawrance (7 out of 7 patents)

5. Eleanor Bagg (7 out of 7 patents)

6. Yi Li (7 out of 23 patents)

7. Jonathan Michael Boulter (5 out of 9 patents)

8. Steven Mark Dunn (4 out of 9 patents)

9. Annelise Brigitte Vuidepot (3 out of 8 patents)

10. Garth Hamilton (2 out of 2 patents)

11. Jonathan Silk (2 out of 2 patents)

12. Claire Gueguen (2 out of 2 patents)

13. Nicholas Pumphrey (2 out of 2 patents)

14. Brian John Cameron (2 out of 2 patents)

15. Bruno Laugel (2 out of 2 patents)

26 patents: Sort by Forward Citations

1. 12180261 - T cell receptors (2024-12-31),

2. 12180260 - T cell receptors (2024-12-31),

3. 12145990 - T cell modification and use thereof (2024-11-19),

4. 12060404 - T cell receptors (2024-08-13),

5. 11929151 - Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex (2024-03-12),

6. 11753456 - T cell receptors (2023-09-12),

7. 11725040 - T cell receptors (2023-08-15),

8. 11572400 - T cell receptors (2023-02-07),

9. 11286289 - T cell receptors (2022-03-29),

10. 11203627 - T cell receptors (2021-12-21),

11. 11124556 - TCR libraries (2021-09-21),

12. 11111301 - T cell modification and use thereof (2021-09-07),

13. 11084862 - T cell receptors (2021-08-10),

14. 11017882 - Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex (2021-05-25),

15. 10689620 - T cells with increased immunosuppression resistance (2020-06-23),

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. Their unique SPEAR T-cell therapy platform enables the engineering of T-cells to target and destroy cancer cells. With a wide range of clinical programs in various cancer indications, Adaptimmune aims to deliver transformative treatments for patients with solid tumors and hematological cancers.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

26 Patents

#9 in Abingdon

#678 in United Kingdom

#24,093 in the World

Abingdon, United Kingdom

Adaptimmune Limited

Forward Citations = 29

24 inventors:

Bent Karsten Jakobsen (11 out of 32 patents)

Peter Eamon Molloy (10 out of 17 patents)

Nicholas Tribble (7 out of 7 patents)

4. William Lawrance (7 out of 7 patents)

5. Eleanor Bagg (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…